UY28145A1 - Nuevos compuestos farmaceuticos - Google Patents

Nuevos compuestos farmaceuticos

Info

Publication number
UY28145A1
UY28145A1 UY28145A UY28145A UY28145A1 UY 28145 A1 UY28145 A1 UY 28145A1 UY 28145 A UY28145 A UY 28145A UY 28145 A UY28145 A UY 28145A UY 28145 A1 UY28145 A1 UY 28145A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical compounds
new pharmaceutical
new
modified
formula
Prior art date
Application number
UY28145A
Other languages
English (en)
Inventor
Kevin Neil Dack
Dafydd Rhys Owen
Christine Anne Louise Watson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY28145A1 publication Critical patent/UY28145A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a inhibidores de NEP de fórmula (1) para tratar trastornos cardiovasculares donde R1 a R5 son como se han modificado en la memoria y reivindicaciones.
UY28145A 2002-12-23 2003-12-22 Nuevos compuestos farmaceuticos UY28145A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0230025.9A GB0230025D0 (en) 2002-12-23 2002-12-23 Novel pharmaceuticals

Publications (1)

Publication Number Publication Date
UY28145A1 true UY28145A1 (es) 2004-07-30

Family

ID=9950328

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28145A UY28145A1 (es) 2002-12-23 2003-12-22 Nuevos compuestos farmaceuticos

Country Status (15)

Country Link
US (1) US20040138274A1 (es)
EP (1) EP1578735A1 (es)
JP (1) JP2006515297A (es)
AR (1) AR042647A1 (es)
AU (1) AU2003285641A1 (es)
BR (1) BR0317644A (es)
CA (1) CA2511360A1 (es)
GB (1) GB0230025D0 (es)
GT (1) GT200300291A (es)
NL (1) NL1025116C2 (es)
PA (1) PA8593601A1 (es)
PE (1) PE20050122A1 (es)
TW (1) TW200420548A (es)
UY (1) UY28145A1 (es)
WO (1) WO2004056787A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005108382A1 (en) * 2004-05-04 2005-11-17 Merck & Co., Inc. 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2005123702A1 (en) * 2004-06-15 2005-12-29 Pfizer Limited Neutral endopeptidase inhibitor polymorph
EP2324886A1 (en) 2005-07-29 2011-05-25 Concert Pharmaceuticals Inc. Novel deuterated analogues of tadalafil
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
BRPI0813212A2 (pt) * 2007-06-26 2014-12-23 Lexicon Pharmaceuticals Inc Métodos de tratamento de doenças e distúrbios mediados por serotonina
US9981926B2 (en) * 2013-12-20 2018-05-29 Novartis Ag Heteroaryl butanoic acid derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820844D0 (en) * 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
HUP0303624A3 (en) * 2001-03-28 2005-06-28 Pfizer N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad and process for preparation of the compounds

Also Published As

Publication number Publication date
GB0230025D0 (en) 2003-01-29
EP1578735A1 (en) 2005-09-28
NL1025116C2 (nl) 2004-10-18
BR0317644A (pt) 2005-12-06
PA8593601A1 (es) 2005-05-24
CA2511360A1 (en) 2004-07-08
PE20050122A1 (es) 2005-01-24
JP2006515297A (ja) 2006-05-25
TW200420548A (en) 2004-10-16
WO2004056787A1 (en) 2004-07-08
US20040138274A1 (en) 2004-07-15
NL1025116A1 (nl) 2004-06-24
GT200300291A (es) 2004-08-13
AU2003285641A1 (en) 2004-07-14
AR042647A1 (es) 2005-06-29

Similar Documents

Publication Publication Date Title
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
SE0202241D0 (sv) Novel Compounds
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
EA200701840A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
ECSP045220A (es) Derivados de n-fenil-2-pirimidin-amina
CY1113306T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
DE602005014621D1 (de) 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n-arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
NO20050740L (no) Ny fremgangsmate for syntesen av (7-metoksy-1-naftyl)acetonitril og anvendelse i syntesen av agomelatin
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
DE60239218D1 (de) Synergistische zusammensetzungen für die behandlung von saatgut
EA200500202A1 (ru) Новый способ синтеза (7-метокси-3,4-дигидро-1-нафталинил)ацетонитрила и его применение при синтезе агомелатина
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
NI200300045A (es) Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
EA200701852A1 (ru) Производные аминокислот
EA200500204A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150513